Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of 14C-labeled R- and S-verapamil in plasma

Bioanalysis

Volumn 2, Issue 3, 2010, Pages 397-405

  Simpson, M ^a   Lappin, G ^b   Keely, B J ^c  

^a Xceleron Ltd   (United Kingdom)

^b Xceleron Inc   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; VERAPAMIL; CARBON;

ACCELERATOR MASS SPECTROMETRY; ACCURACY; ARTICLE; CHIRAL CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MICRODOSE; DRUG STRUCTURE; ENANTIOMER; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LIMIT OF QUANTITATION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; STANDARDIZATION; BLOOD; BLOOD ANALYSIS; CHEMISTRY; ISOLATION AND PURIFICATION; METHODOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); STEREOISOMERISM;

BLOOD CHEMICAL ANALYSIS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MASS SPECTROMETRY; STEREOISOMERISM; VERAPAMIL;

EID: 78751497334     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.7     Document Type: Article

References (22)

1. Garner RC, Lappin G. The Phase 0 microdosing concept. Br. J. Clin. Pharmacol. 61(4), 367-370 (2006).
2. EMEA. Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/SWP/2599 (2004).
3. US FDA. US Department of Health and Human Services. Guidance for industry investigators and reviewers. Exploratory IND Studies (2006).
4. Lappin G, Wagner C, Langer O, Merbel VD. New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis 1(2), 357-366 (2009).
5. Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun. Mass Spectrom. 13(4), 285-293(1999). (Pubitemid 29101097)
6. Lappin GJ. Biomedical accelerator mass spectrometry. Radiotracers Drug Dev. Taylor Francis, Boca Raton, USA (2006).
7. Ings R. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1(7), 1293-1305(2009).
8. Lappin G, Garner C. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499-1506 (2008).
9. Yamane N, Tozuka Z, Sugiyama Y et al. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858(1-2), 118-128 (2007). (Pubitemid 47513599)
10. Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39(3), 93-101 (2001). (Pubitemid 32208536)
11. Young GC, Corless S, Felgate CC, Colthup PV. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5MV tandem accelerator mass spectrometer - fitness for purpose in bioanalysis. Rapid Commun. Mass Spectrom. 22(24), 4035-4042 (2008).
12. Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal. Biochem. 378, 93-95(2008).
13. Madan A, O'brien Z, Wen J et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br. J. Clin. Pharmacol. 67(3), 288-298 (2008).
14. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34, 344-350 (1992).
15. Abrahim A, Luurtsema G, Bauer M et al. Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur. J. Nucl. Med. Mol. Imaging 35(1), 116-123(2008). (Pubitemid 350234143)
16. Tannergren C, Petri N, Knutson L et al. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 74(5), 423-436 (2003). (Pubitemid 37357721)
17. Luurtsema G, Molthoff CF, Windhorst AD et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol. 30(7), 747-751 (2003). (Pubitemid 37123132)
18. Sawicki W. A validated method for the determination of verapamil and norverapamil in human plasma. J. Pharm. Biomed. Anal. 25(3-4), 689-695(2001). (Pubitemid 32493927)
19. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31(8-9), 619-632 (2001). (Pubitemid 32826395)
20. Zhou J, Garner RC, Nicholson S, Kissling CJ, Mayers D. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J. Clin. Pharmacol. 49(12), 1408-1416 (2009).
21. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm. Drug Dispos. 27(7), 329-334 (2006). (Pubitemid 44687786)
22. Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br. J. Clin. Pharmacol. 17(4), 453-458 (1984).